Despite Phase 3 efficacy, Sanofi says its OX40 drug wouldn't meaningfully beat standard care — the latest setback for a once-promising class of immune drugs.
New Triumph trial data show 21–23% weight loss in patients with diabetes or heart disease, setting up a 2027 filing for Lilly's triple-hormone drug.
Patients report hunting across pharmacies for the Lantus SoloStar pen, which Sanofi says is temporarily constrained by rising demand.
Mapping genome architecture and gene activity in the same cells reveals a new layer of dysfunction in Alzheimer's — and possible therapeutic targets.
The CRISPR biotech, which silences genes without cutting DNA, priced a modest offering in a cautious market — a notable reopening for gene-editing listings.
Surgeons warn that colorectal cancer is now the leading cause of cancer death in people under 50, and subtle symptoms are too often dismissed.
A 2026 systematic review finds semaglutide and tirzepatide carry a higher hair-loss signal than older GLP-1 drugs — though the shedding appears reversible.
Prediction-market firm Kalshi has opened contracts on whether drugs will hit their endpoints or win FDA approval, raising fresh insider-trading and ethics concerns.
The company said its next-generation pyruvate kinase activator failed to show enough differentiation, ceding ground to a rival Novo Nordisk therapy.
Ervebo is licensed against one Ebola species, but new human data suggest it may help against the Bundibugyo strain now driving a fast-growing outbreak.
A new American Heart Association statement draws a sharp line between moderate coffee and concentrated caffeine products.
The complaint claims Lilly compared its highest doses against lower doses of Novo’s drugs — escalating a bitter rivalry in the weight-loss market.